ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Glaxo Smith Kline (BIOC.EGX)
Glaxo Smith Kline stock price today, ATLAS forecast and fair value
Egyptian Exchange · Egypt
EGP 258.24▲ +14.81%
Prices as of Oct 27, 2026 · EGP
Chance of rising in 1 month
42%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Glaxo Smith Kline in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Glaxo Smith Kline
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Glaxo Smith Kline a 42% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between EGP 193.42 and EGP 302.88; in 9 out of 10, between EGP 129.96 and EGP 450.76. Estimated annual volatility is 145%.
Price, last 12 months (weekly close)
Key numbers
- 52-week high
- EGP 609.00
- 52-week low
- EGP 55.10
- Operating margin
- 0.0%
- Net margin
- 0.0%
What this means
ATLAS does not publish a fair value for BIOC.EGX right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks BIOC.EGX has traded between EGP 55.10 and EGP 609.00. Today it is 57.6% below that high and 369% above its low.
Want to see everything about Glaxo Smith Kline?
Get started →Plans from €3.99 a month.
Frequently asked questions
What is the chance BIOC.EGX goes up next month?
42%: somewhat worse than a coin flip. In half of the simulated outcomes, BIOC.EGX ends the month between EGP 193.42 and EGP 302.88.
How volatile is BIOC.EGX?
ATLAS estimates annual volatility at 145%. In a typical month, half of the outcomes end between EGP 193.42 and EGP 302.88.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer